ACTH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
| Property | Value | Notes |
|---|---|---|
| Purity assay | RP-HPLC, UV 214 nm | Typical research grade 95 percent or higher |
| Mass confirmation | ESI-MS or MALDI-TOF | Compared with theoretical value |
| Main degradation route | Methionine oxidation | Sulfoxide formation in solution |
| Powder storage | -20 °C, desiccated | Amber vial, minimal headspace |
| Working solution | Sterile water or saline | Prepare fresh; avoid repeated thawing |
纯度评估以反相高效液相色谱为主，通过主峰面积百分比给出粗略结果，再配合电喷雾质谱核对分子量。氨基酸分析可验证组成比例，手性色谱或毛细管电泳用于检查残基构型。常见杂质包括缺失序列的短肽、氧化产物与二聚体。由于多数市售品不附带完整检验报告，独立第三方检测常被用来核实标称值。
从分子层面看，Semax 是线性七肽，没有二硫键、糖基或脂链修饰，N 端为游离氨基，C 端为游离羧基。分子含组氨酸与谷氨酸侧链，因此在水和甲醇等极性溶剂中溶解良好，在非极性溶剂中溶解有限。计算分子量约为 814 Da，与其质子化离子的质荷比吻合，可用于质谱确认。
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
==== Action and reference level ==== WHO presented in 2009 a recommended reference level (the national reference level), 100 Bq/m3, for radon in dwellings. The recommendation also says that where this is not possible, 300 Bq/m3 should be selected as the highest level. A national reference level should not be a limit, but should represent the maximum acceptable annual average radon concentration in a dwelling. The actionable concentration of radon in a home varies depending on the organization doing the recommendation, for example, the EPA encourages that action be taken at concentrations as low as 74 Bq/m3 (2 pCi/L), and the European Union recommends action be taken when concentrations reach 400 Bq/m3 (11 pCi/L) for old houses and 200 Bq/m3 (5 pCi/L) for new ones. On 8 July 2010, the UK's Health Protection Agency issued new advice setting a "Target Level" of 100 Bq/m3 whilst retaining an "Action Level" of 200 Bq/m3. Similar levels (as in the UK) are published by Norwegian Radiation and Nuclear Safety Authority (DSA) with the maximum limit for schools, kindergartens, and new dwellings set at 200 Bq/m3, where 100 Bq/m3 is set as the action level.
Urocortin 2 (Ucn2) is an endogenous peptide in the corticotrophin-releasing factor (CRF) family. Urocortin II is a 38-amino acid peptide that is a member of the CRF family of peptides. Unlike Urocortin I, Urocortin II is highly selective for the CRF2 receptor and does not show affinity for the CRF binding protein.
Another parish church in Bromley is St Mark's, which stands on Westmoreland Road. The present church is the third. The first was built as a temporary iron church in 1884 to cope with Bromley's growing population, on land slightly to the east of the present church, donated by a local man Eley Soames. The road name St Mark's Road preserves the rough location of the former site. The second church was built in brick and stone on the present site, and designed by Evelyn Hellicar, son of the then vicar of St Peter and St Paul's. It was completed in 1898 in the Perpendicular Gothic style and consecrated by William Walsh, Bishop of Dover, on 22 October that year. The tower, though, was not completed until 1904. Like St Peter and St Paul's, St Mark's was heavily damaged in the London Blitz of 1941. Only the tower survived intact. On 3 June 1952, the Duchess of Kent laid the foundation stone of the present church, which was designed by T W G Grant and built by David Nye. Besides the tower, other parts of the fabric of the original church were used in the rebuilding. Inside there are various monuments: to Samuel Ajayi Crowther, John Cole Patteson and Vedanayagam Samuel Azariah, who were all bishops in the Commonwealth. The East Street drill hall was completed in 1872.
=== Articles === Rosen, DR; Siddique, T; Patterson, D; Figlewicz, DA; Sapp, P; Hentati, A; Donaldson, D; Goto, J; O'Regan, JP; Deng, HX; et al. (1993). "Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis". Nature. 364 (6435): 362. Bibcode:1993Natur.364..362R. doi:10.1038/364362c0. PMID 8332197. Gusella, JF; Wexler, NS; Conneally, PM; Naylor, SL; Anderson, MA; Tanzi, RE; Watkins, PC; Ottina, K; Wallace, MR; Sakaguchi, AY; Young, AB; Shoulson, I; Bonilla, E; Martin, JB (1983). "A polymorphic DNA marker genetically linked to Huntington's Disease". Nature. 306 (5940): 234–238. Bibcode:1983Natur.306..234G. doi:10.1038/306234a0. PMID 6316146. S2CID 4320711. Tanzi, RE; Gusella, JF; Watkins, PC; Bruns, GAP; St; George-Hyslop, PH; Van Keuren, ML; Patterson, D; Pagan, S; Kurnit, DM; Neve, RL. (1987). "The amyloid beta protein gene: cDNA cloning, mRNA distribution, and genetic linkage near the Alzheimer locus". Science. 235 (4791): 880–884. Bibcode:1987Sci...235..880T. doi:10.1126/science.2949367. PMID 2949367. Tanzi, RE; McClatchey, AI; Lamperti, ED; V-Komaroff, L; Gusella, JF; Neve, R (1988). "Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease". Nature. 331 (6156): 528–530. Bibcode:1988Natur.331..528T. doi:10.1038/331528a0. PMID 2893290. S2CID 4277294.
Retrieved 26 September 2021 – via Google Books. Jones, Colin (1994). The Cambridge Illustrated History of France. Cambridge University Press. ISBN 978-0-521-66992-4. Jones, Maldwyn Allen (1992). Boorstin, Daniel J. (ed.). American Immigration. University of Chicago Press. ISBN 978-0-226-40633-6. Kagan, Frederick (2007). The End of the Old Order: Napoleon and Europe, 1801–1805. Hachette Books. ISBN 978-0-306-81645-1. Keeling, Drew (1999). "The Transportation Revolution and Transatlantic Migration". Research in Economic History. 19. Keeling, Drew (1 January 2007). "Transport Capacity Management and Transatlantic Migration, 1900–1914". Research in Economic History. 25. Emerald Group Publishing Limited: 225–283. doi:10.1016/s0363-3268(07)25005-0. ISBN 978-0-7623-1370-9.{{cite journal}}: CS1 maint: periodical has ISBN (link) Keen, Benjamin; Haynes, Keith (2012). A History of Latin America. Cengage Learning. ISBN 978-1-133-70932-9. Kennedy, Paul M. (1989). The Rise and Fall of the Great Powers: Economic Change and Military Conflict from 1500 to 2000. Vintage Books. ISBN 978-0-679-72019-5. Knight, Roger (2013). Britain Against Napoleon: The Organization of Victory, 1793–1815. Penguin UK. ISBN 978-0-14-197702-7. Leggiere, Michael V. (2014). Blücher: Scourge of Napoleon. University of Oklahoma Press. ISBN 978-0-8061-4567-9. Malia, Martin Edward (2006). History's Locomotives: Revolutions and the Making of the Modern World. Yale University Press. ISBN 978-0-300-12690-7. McConachy, Bruce (2001). "The Roots of Artillery Doctrine: Napoleonic Artillery Tactics Reconsidered".
Sources: en.wikipedia.org
Cardiomyoplasty is a surgical procedure in which healthy muscle from another part of the body is wrapped around the heart to provide support for the failing heart. Most often the latissimus dorsi muscle is used for this purpose. A special pacemaker is implanted to make the skeletal muscle contract. If cardiomyoplasty is successful and increased cardiac output is achieved, it usually acts as a bridging therapy, giving time for damaged myocardium to be treated in other ways, such as remodeling by cellular therapies.
=== G04BE Drugs used in erectile dysfunction === G04BE01 Alprostadil G04BE02 Papaverine G04BE03 Sildenafil G04BE04 Yohimbin G04BE05 Phentolamine G04BE06 Moxisylyte G04BE07 Apomorphine G04BE08 Tadalafil G04BE09 Vardenafil G04BE10 Avanafil G04BE11 Udenafil G04BE30 Combinations G04BE52 Papaverine, combinations
A tumour vaccine can stimulate the body's immune system, upon exposure to a tumour-specific peptide antigen, by activation or amplification of a humoral and cytotoxic immune response targeted at the specific cancer cells. The study of Schumacher et al. has been shown that this attractive target (the mutation in the isocitrate dehydrogenase 1) from an immunological perspective represents a potential tumour-specific neoantigen with high uniformity and penetrance and could be exploited by immunotherapy through vaccination. Accordingly, some patients with IDH1-mutated gliomas demonstrated spontaneous peripheral CD4+ T-cell responses against the mutated IDH1 region with generation B-cell producing antibodies. Vaccination of MHC-humanized transgenic mice with mutant IDH1 peptide induced an IFN-γ CD4+ T-helper 1 cell response, indicating an endogenous processing through MHC class II, and production of antibodies targeting mutant IDH1. Tumour vaccination, both prophylactic and therapeutic, resulted in growth suppression of transplanted IDH1-expressing sarcomas in MHC-humanized mice. This in vivo data shows a specific and potent immunologic response in both transplanted and existing tumours.
Most spectrophotometers are used in the UV and visible regions of the spectrum, and some of these instruments also operate into the near-infrared region as well. The concentration of a protein can be estimated by measuring the OD at 280 nm due to the presence of tryptophan, tyrosine and phenylalanine. This method is not very accurate since the composition of proteins varies greatly and proteins with none of these amino acids do not have maximum absorption at 280 nm. Nucleic acid contamination can also interfere. This method requires a spectrophotometer capable of measuring in the UV region with quartz cuvettes. Ultraviolet-visible (UV-vis) spectroscopy involves energy levels that excite electronic transitions. Absorption of UV-vis light excites molecules that are in ground-states to their excited-states. Visible region 400–700 nm spectrophotometry is used extensively in colorimetry science. It is a known fact that it operates best at the range of 0.2–0.8 O.D. Ink manufacturers, printing companies, textiles vendors, and many more, need the data provided through colorimetry. They take readings in the region of every 5–20 nanometers along the visible region, and produce a spectral reflectance curve or a data stream for alternative presentations. These curves can be used to test a new batch of colorant to check if it makes a match to specifications, e.g., ISO printing standards. Traditional visible region spectrophotometers cannot detect if a colorant or the base material has fluorescence.
eV, higher than what is predicted in theory for continuum plates of the same thickness, due to nonlocal microstructural constraints such as nonlocal coupling of particle rotational degrees of freedom. On the other hand, resistance to bending is found to be greatly reduced in nanoparticle monolayers that are supported at the air/water interface, possibly due to screening of ligand interactions in a wet environment.
Sources: en.wikipedia.org
=== 1945–1946 === After the end of the war, Amin al-Husayni managed to find his way to Egypt and stayed there until 1959, when he moved to Lebanon. On 22 March 1945, the Arab League was formed. In November 1945, on the urging of Egypt, its leading member, the then seven members of the Arab League (Lebanon, Syria, Iraq, Jordan, Saudi Arabia, Egypt, and Yemen) reconstituted the Arab Higher Committee comprising twelve members as the supreme executive body of Palestinian Arabs in the territory of the British Mandate of Palestine. The committee was dominated by the Palestine Arab Party, controlled by the Husayni family, and was immediately recognised by Arab League countries. The Mandate government recognised the new committee two months later. In February 1946, Jamal al-Husayni returned from exile to Palestine and immediately set about reorganising and enlarging the committee, becoming its acting president. The members of the reconstituted committee as at April 1946 were:
To date, many studies have been conducted on the benefits of selenium intake in reducing the risk of cancer incidence at the nutritional level, indicating that likely selenium functions as an immunostimulator, i.e. reversing the immunosuppression in tumour microenvironment towards antitumour immunity by activating immune cells (e.g. M1 macrophages and CD8+ T-lymphocytes, the elevated number of neutrophils and activated cytotoxic NK cells) and releasing pro-inflammatory cytokines such as IFNγ and TNFα.
Although nilutamide has been found to be effective for transgender hormone therapy, the use of nilutamide in the treatment of prostate cancer, and particularly for other indications that are of a less clinically serious nature, is now discouraged due to the unique adverse effects of the medication, most importantly a high incidence of interstitial pneumonitis. This is an adverse effect that can progress to pulmonary fibrosis and can potentially be fatal. Flutamide is also no longer recommended due to excessive risk of hepatotoxicity and liver failure in men with prostate cancer. For these reasons, newer and safer NSAAs like bicalutamide have largely replaced flutamide and nilutamide, and are now used for relevant indications instead. As selective AR antagonists, flutamide, nilutamide, and bicalutamide have the same mechanism of action, and bicalutamide has similar or greater efficacy to flutamide and nilutamide as an antiandrogen. Bicalutamide is known to have a small risk of elevated liver enzymes and serious liver toxicity. As a result, it is recommended that liver function tests (LFTs) periodically be performed. One protocol that has been recommended is to check LFTs at baseline, at one month, at two months, and then every 6 months thereafter. The risk of elevated liver enzymes and liver failure with bicalutamide appears to be much smaller than with high doses of CPA, which is the most widely used antiandrogen in transgender women in Europe and elsewhere in the world. However, only low doses of CPA are now recommended for use in transgender women.
=== Middle Eastern countries === As of March 2026, Nando's has five restaurants in Bahrain; two in Manama and one each in Amwaj Islands, Isa Town and Saar. In Qatar, Nando's has been established since 2001, with the first restaurant located on Salwa Road. As of October 2022, Nando's has eight branches in Qatar, seven of which are located in Doha while one is in Al Wakrah. In Saudi Arabia, Nando's opened its first restaurant within the country on 12 December 2016 in Riyadh, and opened its first branch in Jeddah on 8 December 2018 As of March 2026, Nando's has nine branches in Saudi Arabia; three in Riyadh, three in Jeddah; and one each in Dhahran, Dammam and Khobar. Nando's opened its first restaurant within the United Arab Emirates in Dubai (along Sheikh Zayed Road) in 2002 and opened its first branch in Abu Dhabi in 2014. As of August 2021, Nando's has 19 branches in the UAE; 13 in Dubai, three in Abu Dhabi and one each in Sharjah, Al Ain and Ras Al Khaimah. As a former market, Israel was home to a successful Nando's franchise network throughout the 1990s and 2000s, with the Israeli operation involving the Brozin brothers alongside the international Nando's business. The first Israeli branch opened in Herzliya in 1993, and by 1996 there were branches in Tel Aviv, Herzliya and Haifa, with plans for further expansion. By March 2004, the network had grown to 15 restaurants. In December 2005, Nando's Israel was acquired by Israeli businessman Yuval Doron's Eddy Global Holdings. Kenny Brozin remained chief executive of the Israeli operation until June 2006.
Artificial bone can be created from ceramics such as calcium phosphates (e.g. hydroxyapatite and tricalcium phosphate), Bioglass and calcium sulfate; all of which are biologically active to different degrees depending on solubility in the physiological environment. These materials can be doped with growth factors, ions such as strontium or mixed with bone marrow aspirate to increase biological activity. Some authors believe this method is inferior to autogenous bone grafting; however, infection and rejection of the graft is much less of a risk, and the mechanical properties such as Young's modulus are comparable to bone. The presence of elements such as strontium can result in higher bone mineral density and enhanced osteoblast proliferation in vivo.
Sources: en.wikipedia.org
Reversed-phase HPLC gives the main purity figure, most often with UV detection near 214 nanometres. Mass spectrometry then confirms the molecular mass. Together the two methods distinguish a correct sequence from a closely related impurity.
The main chemical risks are methionine oxidation and backbone hydrolysis in solution. Moisture and repeated temperature cycling accelerate both processes. Dry powder held cold and desiccated is considerably more stable than any reconstituted preparation.
It holds a medicine registration in Russia, where it has been used clinically for decades. In most other countries it is treated as a research chemical. That split explains the uneven distribution of clinical literature.
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.